Epistem Division Gains Accreditation

Epistem Plc’s Biomarker Division, which Division conducts gene expression analysis to support clinical drug development programs has been awarded Good Clinical Laboratory Practice (GCLP) accreditation status.

The company has developed a proprietary cDNA amplification technique which enables gene expression information to be provided from very small (or degraded) biological samples such as formalin-fixed, paraffinembedded (FFPE) tissue, laser captured microdissected (LCM) samples, single plucked hairs, fractionated blood cells and pinch biopsies. It also provides proprietary panels of biomarkers targeting known oncology and disease specific biological pathways. GCLP accreditation now enables Epistem to support the later stage clinical phases of drug development assuring customers that all studies will be conducted to GCLP quality standards set by the British Association of Research Quality Assurance.

Lydia Meyer-Turkson, Vice President of the Biomarker Division, commented: “Accreditation strengthens our clinical biomarker capabilities enabling us to support regulatory submissions from partners who use our technology and expertise globally.”